FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293758> ?p ?o ?g. }

• W4286293758 endingPage "e16145" @default.
• W4286293758 startingPage "e16145" @default.
• W4286293758 abstract "e16145 Background: In China, the first-line TKI therapy for advanced HCC is a common standard treatment modality. Meanwhile regorafenib combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC). Still，more clinical evidence is needed to optimize second-line treatment for uHCC. In this single-center, retrospective real-world study, we look forward to further clinical benefits of regorafenib combined with PD-1 monoclonal antibody as second-line treatment of uHCC in China. Methods: We reviewed the medical data of 55 patients with HCC and received regorafenib combined with PD-1 monoclonal antibody for second-line treatment from April 2019 to April 2021. Patients were treated with regorafenib combined with PD-1 monoclonal antibody for at least 1 cycle (21days). The progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were observed. Results: The median age was 52 years (range 29-72), 89.1% were male, 78.2% patients had hepatitis B. At study entry, the proportions of patients with Child–Pugh A/B class were 61.8%/36.4% (unknown: 1.8%); the proportions of patients with ECOG performance status 0/1/2 were 70.9%/21.8%/7.3%; the proportions of patients with BCLC stage A/B/C class were 5.5%/9.1%/83.6% (unknown: 1.8%); For prior targeted therapy, the proportion of patients with sorafenib/ lenvatinib / apatinib were 85.5%/9.1%/1.8% (unknown:1.8%), 1patient did not receive targeted therapy. Regorafenib combined with PD-1 monoclonal antibody was used for second-line systemic therapy, the PD-1s used mainly were sintilimab (n = 23), camrelizumab (n = 21), tislelizumab (n = 10); The median initial daily dose was 120 mg (rang,40-160),and the proportions of patients with the initial daily regorafenib dose 160mg/120mg/80mg/40mg were30.9%/16.4%/43.6%/1.8% (unknown :7.3%). The median PFS was 7.9 month (95%CI:5.1, NA), ORR was 27.3%, DCR was 56.4%. Conclusions: The preliminary results of this retrospective real-world study, indicate that regorafenib combined with pd-1 therapy as second-line treatment provide clinical benefits in uHCC patients with a manageable toxicity in Chinese patients. Data will be further collected to reduce bias caused by small sample size and baseline differences." @default.
• W4286293758 created "2022-07-21" @default.
• W4286293758 creator A5015210981 @default.
• W4286293758 creator A5031524217 @default.
• W4286293758 creator A5059621210 @default.
• W4286293758 creator A5070016261 @default.
• W4286293758 creator A5081239588 @default.
• W4286293758 creator A5081534935 @default.
• W4286293758 creator A5082923149 @default.
• W4286293758 date "2022-06-01" @default.
• W4286293758 modified "2023-10-16" @default.
• W4286293758 title "Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma (HCC): A retrospective, real-world study in China." @default.
• W4286293758 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16145" @default.
• W4286293758 hasPublicationYear "2022" @default.
• W4286293758 type Work @default.
• W4286293758 citedByCount "1" @default.
• W4286293758 countsByYear W42862937582023 @default.
• W4286293758 crossrefType "journal-article" @default.
• W4286293758 hasAuthorship W4286293758A5015210981 @default.
• W4286293758 hasAuthorship W4286293758A5031524217 @default.
• W4286293758 hasAuthorship W4286293758A5059621210 @default.
• W4286293758 hasAuthorship W4286293758A5070016261 @default.
• W4286293758 hasAuthorship W4286293758A5081239588 @default.
• W4286293758 hasAuthorship W4286293758A5081534935 @default.
• W4286293758 hasAuthorship W4286293758A5082923149 @default.
• W4286293758 hasConcept C121608353 @default.
• W4286293758 hasConcept C126322002 @default.
• W4286293758 hasConcept C143998085 @default.
• W4286293758 hasConcept C159654299 @default.
• W4286293758 hasConcept C203014093 @default.
• W4286293758 hasConcept C2776248978 @default.
• W4286293758 hasConcept C2776264508 @default.
• W4286293758 hasConcept C2776694085 @default.
• W4286293758 hasConcept C2776999253 @default.
• W4286293758 hasConcept C2778019345 @default.
• W4286293758 hasConcept C2778695046 @default.
• W4286293758 hasConcept C2778822529 @default.
• W4286293758 hasConcept C2780668389 @default.
• W4286293758 hasConcept C526805850 @default.
• W4286293758 hasConcept C542903549 @default.
• W4286293758 hasConcept C71924100 @default.
• W4286293758 hasConcept C90924648 @default.
• W4286293758 hasConceptScore W4286293758C121608353 @default.
• W4286293758 hasConceptScore W4286293758C126322002 @default.
• W4286293758 hasConceptScore W4286293758C143998085 @default.
• W4286293758 hasConceptScore W4286293758C159654299 @default.
• W4286293758 hasConceptScore W4286293758C203014093 @default.
• W4286293758 hasConceptScore W4286293758C2776248978 @default.
• W4286293758 hasConceptScore W4286293758C2776264508 @default.
• W4286293758 hasConceptScore W4286293758C2776694085 @default.
• W4286293758 hasConceptScore W4286293758C2776999253 @default.
• W4286293758 hasConceptScore W4286293758C2778019345 @default.
• W4286293758 hasConceptScore W4286293758C2778695046 @default.
• W4286293758 hasConceptScore W4286293758C2778822529 @default.
• W4286293758 hasConceptScore W4286293758C2780668389 @default.
• W4286293758 hasConceptScore W4286293758C526805850 @default.
• W4286293758 hasConceptScore W4286293758C542903549 @default.
• W4286293758 hasConceptScore W4286293758C71924100 @default.
• W4286293758 hasConceptScore W4286293758C90924648 @default.
• W4286293758 hasIssue "16_suppl" @default.
• W4286293758 hasLocation W42862937581 @default.
• W4286293758 hasOpenAccess W4286293758 @default.
• W4286293758 hasPrimaryLocation W42862937581 @default.
• W4286293758 hasRelatedWork W2806021427 @default.
• W4286293758 hasRelatedWork W3014541357 @default.
• W4286293758 hasRelatedWork W3105390383 @default.
• W4286293758 hasRelatedWork W3110117767 @default.
• W4286293758 hasRelatedWork W4281800895 @default.
• W4286293758 hasRelatedWork W4286293758 @default.
• W4286293758 hasRelatedWork W4286762368 @default.
• W4286293758 hasRelatedWork W4296588654 @default.
• W4286293758 hasRelatedWork W4307503407 @default.
• W4286293758 hasRelatedWork W4320495561 @default.
• W4286293758 hasVolume "40" @default.
• W4286293758 isParatext "false" @default.
• W4286293758 isRetracted "false" @default.
• W4286293758 workType "article" @default.